Table 4.
A summary of current Hepatitis C drugs based on proteases, polymerase, and other degrading enzymes that are in preclinical development or in clinical trials
| Drug Name | Pharma Co. | Class | Clinical Trial Phase |
|---|---|---|---|
| TMC435350 | Tibotec & Medivir | Protease inhibitor | II |
| R1626 | Roche | Nucleoside polymerase inhibitor | II |
| DEBIO-025 | Debiopharm | Cyclophilin inhibitor | II |
| Celgosivir | Migenix | α-glucosidase inhibitor | II |
| BI12202 | Boehringer | Protease inhibitor | I |
| MK-7009 | Merck | Protease inhibitor | I |
| ITMN-191 | InterMune & Roche | Protease inhibitor | I |
| NIM-811 | Novartis | Cyclophilin inhibitor | I |
| R7128 | Pharmasset & Roche | Nucleoside polymerase inhibitor | I |
| PSI-6130 | Pharmasset | Nucleoside polymerase inhibitor | I |
| MK-0608 | Merck | Nucleoside polymerase inhibitor | Preclinical |